Is Sansure Biotech (SHSE:688289) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about

Simply Wall St22:41 ET

Sansure Biotech Inc. (688289.SH): The actual controller and director proposed a mid-term dividend.

On July 17th, Gelon Hui reported that Mr. Dai Lizhong, the actual controller and chairman of Sansure Biotech Inc. (688289.SH), proposed a mid-term dividend plan for 2024, based on the total share capital of the company minus the shares in the company's repurchase special securities account, to distribute a cash dividend of 2.50 yuan (tax-included) per 10 shares to all shareholders, subject to the profit distribution principle stipulated in the Company Law and the premise of ensuring the normal operation and long-term development of the company. The specific profit distribution plan shall be formulated and implemented by the company in combination with its own operating conditions.

Gelonghui FinanceJul 17 07:14 ET

SanSure Biotech Inc.'s announcement on voluntarily disclosing the performance forecast for the first half of 2024.

Sensex a shareJul 3 12:00 ET · Announcements

Sansure Biotech Inc. (688289.SH) received a government subsidy of RMB 46.998 million.

Sansure Biotech Inc. (688289.SH) announced that it has recently received a government subsidy of RMB 46.998 million in industry support funds allocated by the Business and Market Supervision Bureau of Hunan Xiangjiang New Area Management Committee. This subsidy is revenue-related and has been included in the company's annual profit and loss.

Gelonghui FinanceJul 3 07:31 ET

Sansure Biotech Inc. (688289.SH): The net income in the first half of the year is expected to increase by 64% to 80% compared with the same period last year.

On July 3, Gelonhui reported that Sansure Biotech Inc. (688289.SH) estimates that its revenue will reach 710,000,000 yuan in the first half of 2024, an increase of 282,304,200 yuan or 66% compared to the same period last year. The net income attributable to the owners of the parent company is expected to be between 150,000,000 yuan and 165,000,000 yuan in the first half of 2024, an increase of 58,323,900 yuan to 73,323,900 yuan compared to the same period last year, with a year-on-year increase of 64% to 80%.

Gelonghui FinanceJul 3 07:30 ET

Is Sansure Biotech Inc.'s (SHSE:688289) Stock Price Struggling As A Result Of Its Mixed Financials?

Sansure Biotech (SHSE:688289) has had a rough month with its share price down 12%. We, however decided to study the company's financials to determine if they have got anything to do with the price d

Simply Wall StJun 26 00:02 ET